ethyl 7-oxo-7-(8-(pyridin-4-yl)-2,8-diazaspiro[4.5]dec-2-yl)-heptanoate | 336191-25-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂螺癸烷衍生物
• 英文名称: ethyl 7-oxo-7-(8-(pyridin-4-yl)-2,8-diazaspiro[4.5]dec-2-yl)-heptanoate
• 英文别名: ethyl 7-oxo-7-(8-(4-pyridyl)-2,8-diazaspiro[4.5]dec-2-yl) heptanoate；Ethyl 7-oxo-7-(8-pyridin-4-yl-2,8-diazaspiro[4.5]decan-2-yl)heptanoate
• CAS: 336191-25-4
• 化学式: C₂₂H₃₃N₃O₃
• 分子量: 387.522
• InChiKey: LMQXNMZYUMBWSK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  28
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.68
• 拓扑面积：
  62.7
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  ethyl 7-oxo-7-(8-(pyridin-4-yl)-2,8-diazaspiro[4.5]dec-2-yl)-heptanoate 以 乙醇 为溶剂， 以27 mg (89%)的产率得到7-oxo-7-(8-(pyridin-4-yl)-2,8-diazaspiro[4.5]dec-2-yl)heptanoic acid
  参考文献：
  名称：

  Pyridyl-containing spirocyclic compounds as inhibitors of fibrinogen-dependent platelet aggregation

  摘要：

  本发明涉及某些含有取代或未取代吡啶基的螺环化合物，其取代有碱性和酸性功能，可用于抑制血小板聚集，抑制纤维蛋白原与血小板的结合，并预防或治疗血栓形成。

  公开号：

  US20030055244A1
• 作为产物：
  描述：

  8-苄基-2,8-二氮杂-螺[4,5]葵烷 在 palladium dihydroxide sodium hydroxide 、 tris(dibenzylideneacetone)dipalladium (0) 、 氢气 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 、 N,N-二异丙基乙胺 、 三氟乙酸 、 sodium t-butanolate 作用下， 以 1,4-二氧六环 、 甲醇 、 二氯甲烷 、 甲苯 为溶剂， 95.0 ℃ 、689.47 kPa 条件下， 生成 ethyl 7-oxo-7-(8-(pyridin-4-yl)-2,8-diazaspiro[4.5]dec-2-yl)-heptanoate
  参考文献：
  名称：

  Spirocyclic nonpeptide glycoprotein IIb–IIIa antagonists. Part 3: synthesis and SAR of potent and specific 2,8-diazaspiro[4.5]decanes

  摘要：

  The synthesis and biological activity of analogues containing spiro piperidinylpyridine and pyrrolidinylpyridine templates are described. The potent activity of these compounds as platelet aggregation inhibitors demonstrates the utility of the spiro structures as central template for nonpeptide RGD mimics. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00095-1

文献信息

• Pyridyl-containing spirocyclic compounds as inhibitors of fibrinogen-dependent platelet aggregation
  申请人：——

  公开号：US20030055244A1

  公开（公告）日：2003-03-20

  Disclosed are certain substituted or unsubstituted pyridyl-containing spirocyclic compounds substituted with both basic and acidic functionality, which are useful in inhibiting platelet aggregation, inhibiting the binding of fibrinogen to blood platelets, and preventing or treating thrombosis

  本发明涉及某些含有取代或未取代吡啶基的螺环化合物，其取代有碱性和酸性功能，可用于抑制血小板聚集，抑制纤维蛋白原与血小板的结合，并预防或治疗血栓形成。
• PYRIDYL-CONTAINING SPIROCYCLIC COMPOUNDS AS INHIBITORS OF FIBRINOGEN-DEPENDENT PLATELET AGGREGATION
  申请人：Millennium Pharmaceuticals, Inc.

  公开号：EP1224186B1

  公开（公告）日：2003-09-24
• [EN] PYRIDYL-CONTAINING SPIROCYCLIC COMPOUNDS AS INHIBITORS OF FIBRINOGEN-DEPENDENT PLATELET AGGREGATION<br/>[FR] COMPOSES SPIROCYCLIQUES PYRIDILES INHIBITEURS DE L'AGREGATION PLAQUETTAIRE DEPENDANT DES FIBRINOGENES
  申请人：COR THERAPEUTICS INC

  公开号：WO2001030780A2

  公开（公告）日：2001-05-03

  This invention relates to certain substituted or unsubstituted pyridyl-containing spirocyclic compounds substituted with both basic and acidic functionality, which are useful in inhibition of platelet aggregation.
• Spirocyclic nonpeptide glycoprotein IIb–IIIa antagonists. Part 3: synthesis and SAR of potent and specific 2,8-diazaspiro[4.5]decanes
  作者：Mukund M. Mehrotra、Julie A. Heath、Jack W. Rose、Mark S. Smyth、Joseph Seroogy、Deborah L. Volkots、Gerd Ruhter、Theo Schotten、Lisa Alaimo、Gary Park、Anjali Pandey、Robert M. Scarborough

  DOI：10.1016/s0960-894x(02)00095-1

  日期：2002.4

  The synthesis and biological activity of analogues containing spiro piperidinylpyridine and pyrrolidinylpyridine templates are described. The potent activity of these compounds as platelet aggregation inhibitors demonstrates the utility of the spiro structures as central template for nonpeptide RGD mimics. (C) 2002 Elsevier Science Ltd. All rights reserved.